Zykadia (Ceritinib) – NSCLC | HongKong DengYue Medicine

Zykadia Application Scope

Zykadia is an oral ALK inhibitor used to treat ALK-positive metastatic non-small cell lung cancer (NSCLC).

Characteristics

• Ingredients: Ceritinib

• Properties: Tyrosine kinase inhibitor targeting ALK, ROS1, IGF-1R, and InsR; inhibits tumor cell proliferation and survival.

• Packaging Specification: 150 mg film-coated tablets

• Storage:

  • Store at 20°C to 25°C (68°F to 77°F)

  • Excursions permitted between 15°C and 30°C (59°F to 86°F)

• Expiry Date: ​Refer to the packaging for the expiration date; use within the specified period.

• Executive Standard: Refer to the prescribing information provided by the manufacturer.

• Approval Number: FDA approval date: April 29, 2014

• Date of Revision: Refer to the latest prescribing information for the most recent revision date

• Manufacturer: Novartis Pharmaceuticals Corporation

Guidelines for the Use of Zykadia

• Dosage and Administration:

  • Recommended Dose: 450 mg orally once daily with food until disease progression or unacceptable toxicity.

  • Administration: Swallow tablets whole; do not crush or chew.

• Adverse Reactions:

  • Common (≥25%): Diarrhea, nausea, vomiting, abdominal pain, fatigue, decreased appetite.

  • Laboratory Abnormalities: Elevated liver enzymes (ALT, AST), hyperglycemia, increased lipase.

• Contraindications: None listed.

• Precautions:

  • Monitor liver function tests regularly.

  • Assess ECG for QT interval prolongation.

  • Monitor blood glucose levels in diabetic or hyperglycemic patients.

Zykadia Interactions

• Drug Interactions:

  • Avoid concomitant use with strong CYP3A inhibitors or inducers.

  • Ceritinib is a CYP3A substrate and inhibitor; it may affect the metabolism of other drugs.

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.